Amgen Inc. $AMGN Shares Bought by Global Assets Advisory LLC

Global Assets Advisory LLC grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 29.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,111 shares of the medical research company’s stock after buying an additional 1,165 shares during the quarter. Global Assets Advisory LLC’s holdings in Amgen were worth $2,058,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Summit Global Investments increased its stake in shares of Amgen by 41.7% during the third quarter. Summit Global Investments now owns 4,509 shares of the medical research company’s stock worth $1,901,000 after purchasing an additional 1,327 shares in the last quarter. MGO One Seven LLC lifted its stake in Amgen by 74.9% in the 3rd quarter. MGO One Seven LLC now owns 21,758 shares of the medical research company’s stock valued at $9,171,000 after buying an additional 9,321 shares in the last quarter. Aprio Wealth Management LLC lifted its stake in Amgen by 4.7% in the 3rd quarter. Aprio Wealth Management LLC now owns 3,486 shares of the medical research company’s stock valued at $1,469,000 after buying an additional 158 shares in the last quarter. Fusion Capital LLC boosted its holdings in Amgen by 2.1% in the 3rd quarter. Fusion Capital LLC now owns 27,474 shares of the medical research company’s stock worth $11,580,000 after buying an additional 568 shares during the last quarter. Finally, Left Brain Wealth Management LLC boosted its holdings in Amgen by 7.9% in the 3rd quarter. Left Brain Wealth Management LLC now owns 1,742 shares of the medical research company’s stock worth $734,000 after buying an additional 128 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Stock Performance

AMGN opened at $466.01 on Friday. The firm has a market capitalization of $251.94 billion, a PE ratio of 28.96, a PEG ratio of 3.41 and a beta of 0.41. Amgen Inc. has a twelve month low of $288.00 and a twelve month high of $475.65. The firm’s 50-day moving average price is $419.96 and its 200 day moving average price is $374.79. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. Amgen’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts expect that Amgen Inc. will post 22.96 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be given a $2.52 dividend. The ex-dividend date is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. Amgen’s dividend payout ratio is 62.65%.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Dividend support: Amgen’s dividend announcement helped reinforce the stock’s income appeal and contributed to its move to a new 1-year high. Amgen Sets New 1-Year High Following Dividend Announcement
• Positive Sentiment: Analyst endorsement: RBC Capital reaffirmed its Buy rating, providing continued Wall Street support ahead of the earnings release. RBC Capital Reaffirms Buy Rating
• Positive Sentiment: Pipeline and rare-disease progress: New Phase 3 dazodalibep data in Sjögren’s disease, UPLIZNA updates and a rare-disease diagnostic collaboration support Amgen’s longer-term growth narrative beyond its established products. Rare Disease Updates
• Neutral Sentiment: Key near-term catalyst: Amgen will report third-quarter 2026 results after the market close on November 3. The current consensus EPS estimate cited in previews is $5.79, making earnings, guidance and management commentary important tests for the recent rally. Amgen Q3 2026 Preview
• Negative Sentiment: Profitability concerns: Management has warned of rising expenses, while MariTide development is consuming substantial cash. Investors are watching whether growth from Repatha and TEZSPIRE can offset higher costs and protect margins. Amgen Faces Rising Expenses Ahead of Q3 Results
• Negative Sentiment: Valuation and execution risk: A skeptical earnings preview highlights concerns about the CFO transition, spending growth and whether Amgen can meet expectations after a substantial year-to-date advance. Amgen Earnings Preview

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. UBS Group boosted their price objective on Amgen from $430.00 to $470.00 and gave the stock a “buy” rating in a research note on Friday, October 9th. Piper Sandler raised their target price on Amgen from $427.00 to $457.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. Canaccord Genuity Group lifted their price target on Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. Citigroup boosted their price target on Amgen from $345.00 to $405.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Finally, Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a research note on Sunday, October 18th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, Amgen has an average rating of “Hold” and a consensus target price of $389.71.

Insider Buying and Selling

In related news, SVP Nancy Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 6,222 shares of company stock valued at $2,540,926 over the last 90 days. Company insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.